1. Complexes of human trypsin and human granulocyte elastase with a,-anti-trypsin and az-macroglobulin were isolated and injected intravenously into human volunteers.
Introduction
Previous studies of interactions between the pancreatic proteases and the protease inhibitors of plasma have shown high affinities of al-anti-trypsin and az-macroglobulin for proteases in virro (Laurell & Jeppsson, 1975) . These proteins were responsible in the dog for the inhibition and clearance of protease from blood and extracellular fluid (Ohlsson, 1971a, b, c) . The half-life of A2M-protease(') complexes in the circulation was only 5-10 min and followed first-order kinetics. Complexes of AAT with protease, however, persisted longer in the circulation, with half-lives that varied between 30 and 45 min. Transfer was observed of protease from AAT-protease complexes to AzM, but transfer did not occur from A2M. The AzM-protease complexes were rapidly absorbed and digested by cells of the reticuloendothelial system. The intravenous injection of active enzyme in the dog resulted in shock and death whenever the quantity of enzyme exceeded the binding capacity of the plasma A,M (Ohlsson, Ganrot & Laurell, 1971 ). This occurred with trypsin injections even though the circulating AAT was often less than half saturated with enzyme at the time of full AzM saturation. These facts suggested a key role for AzM in protection against protease in the dog.
Observations on the interactions of proteases with protease inhibitors in vivo in man are few and contradictory. Complexes of AIM with plasmin were rapidly removed from the circulation but evidence was presented by NilChn & Ganrot (1967) that the complexes retained some activity in the circulation, with proteolysis that was restricted to polypeptides. Data presented by Blatrix, Amouch, Drouet & Steinbuch (1973) suggested that AzM-trypsin com-87 plexes were rapidly eliminated from the blood. But the functional activity of the proteins in that study seems questionable since the inhibitors would have been supersaturated with enzyme as reported. Saturation of inhibitors with enzyme risks proteolysis of the inhibitors, with drastic conformational changes invoked by cleavage.
The purpose of this investigation was to measure persistence in the circulation of complexes between major inhibitors of plasma and natural proteases. Insofar as possible, the preparation of the complexes was designed to ensure native functional states of the proteins. Experience from dog studies permitted us to draw conclusions about the metabolism of enzyme-inhibitor complexes in man from a limited number of experiments since the catabolic rates found were closely similar in the two species. Trypsin in the circulation is so distinctly abnormal that data on trypsin complexes may apply only to few disease states. But the interactions of A2M and AAT with the elastase derived from the granulocyte must be of fundamental importance. Enzymes released from granulocytes and the metabolism of their enzymeinhibitor complexes could conceivably influence morbidity and mortality in many diseases.
Material and methods

Preparations
Human granulocyte elastase (Ohlsson & Olsson, 1974) and human cationic trypsin (Ohlsson & Skude, 1976) were purified as previously described. The purified enzymes were electrophoretically homogeneous on agarose and polyacrylamide disc electrophoresis (pH 4.3). AAT was isolated as described by Jeppsson & Laurell (1974) . Rabbit antisera against human AAT and A2M were available in the laboratory. AAT and A2M in plasma were estimated with electroimmunoassay (Laurell, 1972) .
The elastase and the trypsin were labelled with l J I I and AAT with lz5I with the lactoperoxidase method (Thorell & Johansson, 1971 ). Low-molecular-weight radioactive material was separated by gel filtration on Sephadex G-25 in columns (0.9 cm x 10 cm) equilibrated with acetate buffer (50 mmol/l; pH 4.01, or Tris-HC1 buffer (50 mmol/l; pH 7.4) for 1251-labelled AAT, in NaCl solution (05 mol/l). The labelled enzymes retained more than 90% of their proteolytic activity. The specific radioactivity of the labelled proteins was 0.5 fiCi/mg for trypsin, 0.6 fiCi/mg for elastase and 0.5 pCi/mg for AAT.
Gel filtration of plasma and fractions on Sephadex G-200 was performed at 4" C in columns (2.5 cm x 55 cm) equilibrated with Tris-HC1 buffer (40 mmol/l ; pH 7.4) containing NaCl(O.1 mol/l). Samples (3 ml) were fractionated at an elution rate of 15 ml/h. Fractions (4 ml) were collected and protein content was estimated by measuring extinction at 280 nm. Radioactivity of blood specimens was analysed in a Gamma spectrometer with a well scintillation detector.
All preparations were sterilized by Millipore filtration.
Experimental procedures
The elimination of the AAT and A2M complexes was first studied in the authors and then in two additional healthy volunteer subjects who were fully informed about the risks involved (for the number of experiments see Table 1 ). We used fresh plasma for the preparation of complexes to be injected. In addition the elimination of AAT was studied in one of the authors: the predominant type of AAT, i.e. Pi-MM, was used in this study.
Preparation of ' 'I-labelled trypsin and "I-labelled granulocyte elastase complexes with AAT and A M
Human serum (2 rnl) was rapidly mixed with 1 mg of labelled human cationic trypsin (or human granulocyte elastase) in 1.0 ml of Tris-HC1 buffer (40 mmol/l; pH 7-4) containing NaCl (0.1 mol/l) and CaCL (50 mmol/l) and incubated at room temperature for 10 min. Proteins of the resultant mixture were then separated by gel filtration on Sephadex G-200. Radioactivity was measured and those fractions containing complexes of trypsin (or elastase) with AAT and A2M were separately pooled.
The labelled AzM-protease complexes were available for intravenous infusion within 3 4 h and the corresponding AAT complexes within 15 h after the blood had been drawn from the test subject. The investigators were of the AAT type Pi-MM, and the enzymes added to plasma resulted in about half saturation of the trypsin (elastase) binding capacity of the plasma. All proteins, including AAT, were injected in an amount corresponding to about 25 pCi of radioactivity.
Results
Intravenous administration of A I M complexes formed in vitro with 'I-labelled trypsin (or 311-labelled elastase)
This was not followed by any changes in blood pressure, pulse or breathing frequency and the test subjects did not notice any discomfort. The disappearance of radioactivity followed a singleexponential function until about 75% of the complexes had been eliminated ( Fig. 1 and Fig. 2) . In general, metabolic behaviour was similar for both enzyme complexes. The half-lives were 9-10 min for the '311-labelled trypsin complexes and 12 min for the corresponding A2M-' 'I-labelled elastase complexes (Table 1 ). An initial decrease in l3'1 was followed in about 30 min by a period during which radioactivity increased slightly ( Fig. 1 and Fig. 2) . At this time, dialysable radioactivity appeared in the urine. Plasma specimens obtained 5 min after the injection of AzM complexes with trypsin or elastase were fractionated by gel filtration with Sephadex G-200 and analysed for radioactivity. More than 99% (99.0-99-6%) of radioactivity in these specimens was bound to A2M. Similar analyses of plasma obtained 2 h after the injection of complexes failed to reveal radioactivity in the AIM fractions. All the radioactivity present was dialysable. Radioactivity measured by an external counter over the liver reached a maximum about 30 min after the injection of the 1311-labelled trypsin complexes (Fig. 1) and about 40 min after the injection of the corresponding A2M-' 'I-labelled elastase complexes (Fin. 2).
Intravenous administration of AAT complexes jormed in vitro with 'I-labelled trypsin-or 1311-labelled elastase
The injections of AAT-' 311-labelled trypsin complexes were accompanied by slight dizziness, which lasted about 30-60 s in all subjects studied. Simultaneously the blood pressure fell from 130/80 mmHg 
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FIG. 2. Elimination of radioactivity from the plasma of one individual after intravenous injection of AzM-'~'Ilabelled elastase complexes (0-O),
and AAT-1311-labelled elastase complexes and '251-labelled
AAT (+H).
Radioactivity measured by external counter over the liver is also shown for A2M-13'I-labelled elastase complexes (0 ---0 ) and AAT-1311-labelled elastase complexes (0 ---0).
to 95/60 mmHg in one of the subjects while the pulse rate increased about 30%. These effects were transient. The injections of AAT complexes with 1 3 ' 1 -labelled elastase were not associated with any reactions, symptomatic or circulatory. About half of the radioactivity measured in the blood 5 min after the injection of AAT-'311-labelled trypsin complexes still remained in the plasma 3 3 h later (Fig. 1) . The half-life of AAT-' 'I-labelled elastase complexes was significantly shorter, 1.Ck1.5 h (Fig. 2) . Plasma specimens obtained 5 rnin after the injection of these complexes were fractionated within 30 min by filtration through Sephadex (3-200. These studies revealed that the major part was still bound to AAT. About 5% (456.3%) of the total radioactivity was, however, recovered with A,M after injection of AAT-l3 'I-labelled trypsin complexes and about 8 (6.2-9.5 %) after the injection of AAT-' 'I-labelled elastase complexes. Specific antisera against the inhibitors caused precipitation of more than 90% (905-94.2%) of the radioactivity in each of these fractions. Both trypsin and elastase were thus transferred from AAT to A2M. Radioactivity monitored continuously over the liver reached a maximum 60-70 min after injection of AAT-I 311-labelled trypsin complexes, and 50-60 min after AAT-' 31Llabelled elastase complexes (Fig.  I and Fig. 2) .
Intraoenous administration of l 2 sI-labelled A A T
This was not followed by any circulatory symptoms or discomfort. The elimination curve obtained is shown in Fig. 1 and Fig. 2 for reference.
Discussion
Preliminary experiments in this laboratory had revealed that trypsin could alter the electrophoretic properties of isolated, pure AAT and of AAT-trypsin complexes even before the trypsin concentration exceeded the binding capacity of the AAT. But this effect was small with albumin concentrations similar to those found in plasma. We produced protease complexes for the present experiments by the addition of protease to fresh serum in quantities calculated not to exceed half saturation of AAT. Serum was preferable to purified inhibitors for the formation of complexes in order to avoid cleavage of the AAT and AAT-protease complexes and to minimize the risks of undesirable reactions on injection.
Our results agree with our earlier findings in the dog (Ohlsson, 1971a, b; Ohlsson ef al., 1971), and show that A,M-protease complexes are cleared from the circulation in man much faster than AAT-protease complexes. In the dog, we found that the reticuloendothelial cells absorb the complexes (Ohlsson, 1971~) . This high rate of elimination suggests that blood is cleared of A2M complexes quantitatively on single passage through those organs with efficient reticuloendothelial-sieve mechanisms such as the liver, bone marrow and spleen. The liver scan data are also consistent with this assumption.
This high rate of clearance deserves special consideration because it indicates that the interaction between the large inhibitor (rnol. wt. 725 000) and these small enzymes (mol. wt. 24000 and 34000) results in a conformational change of the inhibitor molecule that is immediately recognized by thereticuloendothelial cells. It has been proposed that the proteases occupy a surface gap (or pocket) on the A2M molecule which traps the enzyme molecule as soon as it digests a sensitive peptide in the pocket of the inhibitor (Barret & Starkey, 1973) . It is interesting that such an apparently small alteration can result in immediate molecular suicide. Whether this triggers a chain reaction analogous to the sequence which eliminates antigen-antibody complexes from the circulation is not known. Receptors in the reticuloendothelial cells may possibly identify deformed inhibitor molecules for removal but such receptors have not been identified. The slightly higher rate of elimination for the smaller enzyme, trypsin (rnol. wt. 24OOO), over that of the larger elastase (mol. wt. 34 OOO) suggests that the enzyme size may influence the degree of closure of the A2M pocket. If the smaller enzyme provoked the more pronounced surface change we should expect the result observed. This concept seems worthy of testing with enzymes of more widely differing sizes.
The elimination of AAT-protease complexes from the circulation was considerably slower than the elimination of A2M-protease complexes. Even so, there was a great difference between the elimination of AAT complexes (to.s = 60-90 min with elastase) and the curve obtained for free AAT, which is in agreement with the normal metabolic turnover (to., = 4 days) (Laurel1 & Jeppsson, 1975) . The implications are similar for AAT to those already discussed for A2M. The clearance of AAT-protease complexes is not adequately expressed as a simple exponential decay. The explanation may be simply that AAT-enzyme complexes are only gradually eliminated from the circulation, or that the complexes dissociate. The data fit either possibility ( Fig.  1 and Fig. 2 ). Evidence for dissociation was obtained when the injection of AAT-protease complexes resulted in the appearance of A2M-protease complexes in the blood 5 min after injection. We cannot exclude the possibility that enzyme-transfer occurred at the time of, or just after, the blood samples were obtained. But the transfer of enzyme from AAT to A2M is consistent with our other observations that AAT-enzyme complexes readily yield enzyme to the bovine lung trypsin inhibitor aprotinin (Trasylol), an inhibitor which binds enzymes with higher energy than AAT. We think there is a slow dissociation of AAT-protease complexes, and there may be some differences in rate with different proteases. The association of AAT with elastase, for example, seems of significantly higher energy than the association of AAT with trypsin.
It seems logical to propose that every protease molecule released from AAT will be bound either by another AAT molecule, by A2M, or encounter substrate. In the case of A2M, the result is immediate clearance from plasma. Thus elimination will be influenced by the rate of dissociation of complex and by the ratio of free AAT to AIM molecules in the plasma. Implicit in this concept is the idea that AAT serves as a carrier protein for proteases, particularly in the extracellular space where the concentration of A2M is low. The diffusion of AAT is much greater than A2M because it has a much smaller hydrodynamic volume. The hypothesis that AAT is mainly a carrier protein has support from the results of our preliminary studies on dogs. We injected complexes which had double labels, '2sII-labelled AAT and 'I-labelled trypsin. The turnover rate of AAT from these complexes as reflected by the disappearance of lZsI was much slower than the turnover of trypsin as reflected by disappearance of 13'1 (Ohlsson & Delshammar, 1975 ).
An additional point in need of clarification is whether the reversible linkage of proteases to AAT occasions chemical alterations that impair inhibitor function. The key role of A2M for protection against protease is emphasized by the present results in man. Further studies of A2M may document this role in diseases associated with the release of protease into the tissues.
